SWOG clinical trial number
S1221
"Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer."
39% Accrual
Accrual
39%
Closed
Phase
39% Accrual
Accrual
39%
Abbreviated Title
BRAF Mutant Metastatic Cancer
Status Notes
The study referenced above was temporarily closed to accrual on 10/31/2016.
Due to drug supply on this study, the study will be switched from temporarily closed to permanently closed with the same status date of 10/31/2016.
Due to drug supply on this study, the study will be switched from temporarily closed to permanently closed with the same status date of 10/31/2016.
Activated
07/01/2013
Participants
Limited: Institutions Listed on the Title Page
Research committees
Melanoma
Gastrointestinal Cancer
Leukemia
Treatment
Dabrafenib
GSK2141795
Trametinib Dimethyl Sulfoxide
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2303
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase